Dihexa is a synthetic hexapeptide (six amino acid chain) derived from angiotensin IV that activates a brain growth-factor pathway to promote the formation of new synaptic connections, and is investigated for cognitive enhancement and neurodegeneration.
What it does
Dihexa works by activating the HGF/c-Met pathway — HGF (hepatocyte growth factor) is a protein that drives cell growth and repair, and c-Met is its receptor on cell surfaces. Dihexa stabilizes HGF in its active two-part (dimeric) form and pushes the conversion of the inactive precursor (proHGF) into the active version. Once HGF binds c-Met, the receptor phosphorylates itself (adds chemical tags that switch it 'on'), triggering two downstream signaling cascades — RAS/MAPK and PI3K/AKT — that tell neurons to grow more dendritic spines (the small branches that receive signals from neighboring neurons) and form denser synaptic connections. The result, at least in cell and animal models, is a measurable increase in neuronal connectivity al. 2013.
In cell culture, Dihexa has been reported to be roughly 10 million times more potent than BDNF (brain-derived neurotrophic factor, the most studied neuroplasticity protein) at inducing synaptogenesis (new synapse formation). That number comes from in vitro work and should not be read as a clinical dose comparison, but it does indicate high receptor-level activity al. 2013.
Dihexa crosses the blood-brain barrier (the selective membrane separating the bloodstream from brain tissue) when taken orally or applied topically — a practical advantage over many peptides that require injection to reach the CNS. The same HGF/c-Met pathway that makes it interesting for cognition is, however, a well-documented oncogenic (tumor-promoting) pathway: c-Met overactivation is a driver of tumor invasion and metastasis in several cancer types. That dual nature is the most important thing to understand about this compound.
What the evidence shows
Cognitive enhancement and memory in aging Rodent evidence only; no published human trials
In aged rat models, Dihexa restored both synaptic density and cognitive performance on spatial memory tasks to levels comparable to young animals al. 2013. The same study evaluated metabolically stabilized angiotensin IV analogs — Dihexa being the lead compound — and found procognitive effects consistent with HGF/c-Met activation in the hippocampus, the brain region central to memory consolidation al. 2013. No peer-reviewed human trials have been published. All human use is anecdotal or from unregistered self-experimentation.
Neurodegeneration (Alzheimer's / dementia models) Rodent evidence only; mechanistic rationale is plausible but unconfirmed in humans
The procognitive and antidementia framing comes directly from the original pharmacology research, which positioned Dihexa as a candidate for conditions involving synaptic loss al. 2013. The HGF/c-Met pathway is genuinely implicated in neuronal survival and plasticity, giving the hypothesis a reasonable mechanistic basis. However, 'plausible mechanism in rats' is a long way from demonstrated efficacy in human neurodegenerative disease, and no clinical trials have tested this indication.
How it's used
In studies and self-reported protocols, oral doses range from 8–25 mg daily, often categorized as low (8–10 mg), moderate (15–20 mg), or high (25 mg). Topical application has also been reported, though absorption data for that route in humans is absent. The half-life is approximately 10 hours, supporting once-daily dosing. Most self-reported protocols time the dose in the morning with food. There are no established clinical dosing guidelines; the ranges above are drawn from the preclinical literature and anecdotal human reports.
Side effects and safety
Self-reported mild effects include headache and mild anxiety. At higher doses or in sensitive individuals, overstimulation, insomnia, and irritability have been noted. The most serious concern is theoretical but well-grounded in cancer biology: Dihexa is an agonist of the c-Met receptor, a pathway that drives tumor growth, invasion, and metastasis in multiple cancer types when overactivated. This makes it an absolute contraindication in anyone with an active brain tumor or a personal history of c-Met-driven cancers. Pregnancy is also an absolute contraindication given the growth-factor activity. A history of seizures is considered a relative contraindication. Long-term safety in humans is entirely unknown — no controlled human studies exist, so cumulative effects, cancer risk over extended use, and interactions with existing conditions have not been characterized.
Bottom line
Dihexa has genuine and interesting pharmacology backed by solid rodent data, but zero published human trials — making any cognitive benefit in people speculative. The oncogenic potential of sustained c-Met agonism is a real, not theoretical, concern that should weigh heavily in any personal risk assessment. Anyone with a cancer history, active malignancy, or pregnancy should not use it.